Press Releases October 7, 2026 08:00 AM

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum

Akebia Therapeutics to Present at Virtual U.S. Bancorp I BTIG Kidney Health Forum

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
AKBA

Akebia Therapeutics announced that key executives will participate in one-on-one meetings at the virtual U.S. Bancorp I BTIG Kidney Health Forum, discussing their commercial products and clinical pipeline focused on rare kidney diseases.

Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum
AKBA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Akebia Therapeutics focuses on treatments for kidney diseases, including rare kidney conditions.
  • Senior executives will engage with investors at a well-regarded kidney health forum to highlight their commercial and pipeline assets.
  • The company is positioned within the biopharmaceutical sector with a specialization in nephrology-related therapies.

WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Dr. Steven Burke, Chief R&D and Medical Officer, and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in one-on-one meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum on October 14, 2026.

During meetings, management will discuss its commercial products and clinical stage, differentiated pipeline assets for rare kidney diseases.

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Waltham, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
[email protected]  


Risks

  • The success of Akebia's clinical-stage assets is uncertain and depends on clinical trial outcomes and regulatory approvals.
  • Market adoption of their commercial products can be subject to competitive and reimbursement challenges.
  • Investor interest and sentiment could fluctuate based on broader biotech market conditions and developments in the rare kidney disease treatment landscape.

More from Press Releases

CNH Names Paul Dick, President, North America Nov 20, 2026 Harmony Biosciences to Participate in Upcoming Investor Conferences Nov 19, 2026 Pure Cycle Announces Record Financial Results For the Year Ended August 31, 2026 Nov 18, 2026 Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026